| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
310,240,000 |
| Market
Cap: |
13.15(B) |
| Last
Volume: |
2,916,579 |
Avg
Vol: |
2,443,284 |
| 52
Week Range: |
$32.38 - $46.61 |
|
| Level
I Sector: |
Industrials |
| Level
II Sector: |
Diversified Services |
| Level
III Sector: |
Research Services |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : 11.8 |
| Insider 6 Months : 11.8 |
| Insider 3/6 Months : 24 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Exelixis is an oncology-focused biotechnology company that engages in the discovery, development and commercialization of new medicines for cancers. Co.'s products include: CABOMETYX® (cabozantinib) tablets approved for renal cell carcinoma, and for previously treated hepatocellular carcinoma; and COMETRIQ® (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. The other products are: COTELLIC® (cobimetinib), an inhibitor of MEK approved as part of a combination regimen to treat forms of melanoma; and MINNEBRO® (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
27,532 |
27,532 |
27,532 |
642,532 |
| Total Buy Value |
$1,187,235 |
$1,187,235 |
$1,187,235 |
$13,853,924 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
1 |
4 |
| Total Shares Sold |
245,235 |
245,235 |
1,007,274 |
1,879,706 |
| Total Sell Value |
$10,490,620 |
$10,490,620 |
$42,655,760 |
$67,526,158 |
| Total People Sold |
4 |
4 |
14 |
15 |
| Total Sell Transactions |
6 |
6 |
30 |
54 |
| End Date |
2025-10-05 |
2025-07-04 |
2025-01-03 |
2024-01-04 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Caligan Partners Lp |
See Remarks |
– • – |
2025-11-25 |
4 |
B |
$43.12 |
$1,187,235 |
I/I |
27,532 |
1,553,262 |
2.1 |
1% |
|
| Haley Patrick J. |
EVP, Commercial |
• – – |
2025-11-21 |
4 |
S |
$42.58 |
$1,194,071 |
D/D |
(28,043) |
374,029 |
|
-3% |
|
| Aftab Dana |
EVP, Research and Development |
• – – |
2025-11-21 |
4 |
GD |
$0.00 |
$0 |
D/D |
24,000 |
640,778 |
|
- |
|
| Haley Patrick J. |
EVP, Commercial |
• – – |
2025-11-20 |
4 |
S |
$41.77 |
$1,431,757 |
I/I |
(34,187) |
0 |
|
-4% |
|
| Haley Patrick J. |
EVP, Commercial |
• – – |
2025-11-20 |
4 |
S |
$42.11 |
$421,100 |
D/D |
(10,000) |
402,072 |
|
-4% |
|
| Oliver Bob |
Director |
– • – |
2025-11-17 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,044 |
42,282 |
|
- |
|
| Morrissey Michael M |
President and CEO |
• • – |
2025-11-12 |
4 |
GD |
$0.00 |
$0 |
I/I |
80,000 |
1,714,404 |
|
- |
|
| Morrissey Michael M |
President and CEO |
• • – |
2025-11-12 |
4 |
GA |
$0.00 |
$0 |
I/I |
101,548 |
1,794,404 |
|
- |
|
| Morrissey Michael M |
President and CEO |
• • – |
2025-11-12 |
4 |
GD |
$0.00 |
$0 |
D/D |
101,548 |
1,416,692 |
|
- |
|
| Papadopoulos Stelios |
Director |
– • – |
2025-11-12 |
4 |
S |
$43.55 |
$4,355,000 |
D/D |
(100,000) |
1,189,228 |
|
0% |
|
| Aftab Dana |
EVP, Research and Development |
• – – |
2025-11-11 |
4 |
S |
$42.50 |
$2,056,278 |
D/D |
(48,383) |
664,778 |
|
-1% |
|
| Morrissey Michael M |
President and CEO |
• • – |
2025-11-11 |
4 |
GD |
$0.00 |
$0 |
I/I |
160,000 |
1,692,856 |
|
- |
|
| Beckerle Mary C |
Director |
– • – |
2025-11-11 |
4 |
S |
$41.90 |
$1,032,414 |
D/D |
(24,622) |
21,380 |
|
-1% |
|
| Beckerle Mary C |
Director |
– • – |
2025-11-11 |
4 |
OE |
$23.24 |
$134,420 |
D/D |
5,784 |
46,002 |
|
- |
|
| Hefti Brenda |
SVP and General Counsel |
• – – |
2025-11-07 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
5,527 |
|
7% |
|
| Hefti Brenda |
SVP and General Counsel |
• – – |
2025-11-07 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
90,441 |
|
7% |
|
| Aftab Dana |
EVP, Research & Development |
• – – |
2025-10-08 |
4 |
A |
$0.00 |
$0 |
D/D |
50,673 |
713,161 |
|
- |
|
| Wyszomierski Jack L |
Director |
– • – |
2025-06-03 |
4 |
AS |
$43.09 |
$324,683 |
D/D |
(7,535) |
358,882 |
|
-11% |
|
| Eckhardt Sue Gail |
Director |
– • – |
2025-06-02 |
4 |
AS |
$42.74 |
$805,140 |
D/D |
(18,838) |
21,380 |
|
-10% |
|
| Smith Julie |
Director |
– • – |
2025-05-29 |
4 |
A |
$0.00 |
$0 |
D/D |
9,812 |
20,590 |
|
- |
|
| Beckerle Mary C |
Director |
– • – |
2025-05-29 |
4 |
A |
$0.00 |
$0 |
D/D |
9,812 |
40,218 |
|
- |
|
| Heyman Tomas J. |
Director |
– • – |
2025-05-29 |
4 |
A |
$0.00 |
$0 |
D/D |
9,812 |
42,282 |
|
- |
|
| Papadopoulos Stelios |
Director |
– • – |
2025-05-29 |
4 |
A |
$0.00 |
$0 |
D/D |
9,812 |
1,289,228 |
|
- |
|
| Eckhardt Sue Gail |
Director |
– • – |
2025-05-29 |
4 |
A |
$0.00 |
$0 |
D/D |
9,812 |
40,218 |
|
- |
|
| Freire Maria C |
Director |
– • – |
2025-05-29 |
4 |
A |
$0.00 |
$0 |
D/D |
9,812 |
100,819 |
|
- |
|
1113 Records found
|
|
Page 1 of 45 |
|
|
1.18 (2.71%) 
